NOVOBIOTIC PHARMACEUTICALS, LLC
Biotech · Private
Teixobactin (TXB), a novel antibiotic molecule that binds dual bacterial targets (lipid II and lipid III) to treat drug-resistant tuberculosis and serious infections
- Grants
- $20M
- 27 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 30
- 9 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Drug Discovery from Slow Growing and Rare Microbial Species | $981,599 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Preclinical development of teixobactin, a new antibiotic | $1,490,624 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Specific anti-TB compounds from uncultured bacteria | $219,069 | |
| Federal grant | Department of Health and Human Services · Phase I · Selective agents against C. difficile infection | $297,718 | |
| Federal grant | Department of Health and Human Services · Phase I · Microbial symbionts of marine invertebrates for antibiotic discovery | $224,356 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of teixobactin, a new antibiotic | $740,926 | |
| Federal grant | Department of Health and Human Services · Phase II · Exploratory Chemistry on a new antibiotic | $746,210 | |
| Federal grant | Department of Health and Human Services · Phase II · Exploratory Chemistry on a new antibiotic | $738,383 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Antibiotics from Marine Invertebrate Microbes | $586,229 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical development of Novo29, a new antibiotic | $231,409 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of teixobactin, a new antibiotic | $999,040 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Antibiotics from Marine Invertebrate Microbes | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of teixobactin, a new antibiotic | $996,881 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of Novo29, a new antibiotic | $999,992 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of Novo29, a new antibiotic | $987,424 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of teixobactin, a new antibiotic | $999,567 | |
| Federal grant | Department of Health and Human Services · Phase I · Antibiotic discovery from a new genus of uncultured bacteria. | $299,505 | |
| Federal grant | Department of Health and Human Services · Phase II · Teixobactin Development for Anthrax | $999,978 | |
| Federal grant | Department of Health and Human Services · Phase I · Antibiotic discovery from a new genus of uncultured bacteria. | $296,521 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of Novo29, a new antibiotic | $977,463 | |
| Federal grant | Department of Health and Human Services · Phase II · Teixobactin Development for Anthrax | $996,402 | |
| Federal grant | Department of Health and Human Services · Phase II · Teixobactin Development for Anthrax | $992,770 | |
| Federal grant | Department of Health and Human Services · Phase II · Teixobactin Development for Tuberculosis | $999,995 | |
| Federal grant | Department of Health and Human Services · Phase I · Antifungal discovery from previously uncultivated bacteria | $299,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Teixobactin Development for Tuberculosis | $996,278 | |
| Federal grant | Department of Health and Human Services · Phase I · Antifungal discovery from previously uncultivated bacteria | $295,757 | |
| Federal grant | Department of Health and Human Services · Phase II · Teixobactin Development for Tuberculosis | $992,480 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1485 | Treovir, Inc. | — | $133K |
| 1486 | APTINYX, INC. | — | $95M |
| 1487 | Selva Nexus, Inc. | — | $50K |
| 1488 | NOVOBIOTIC PHARMACEUTICALS, LLC | — | — |
| 1489 | Cellevate Inc. | — | $25K |
| 1490 | Pinto Inc. | — | $20K |
| 1491 | CERACUITY, INC. | — | $3K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Pharmaceutical Compositions Comprising Teixobactingranted
- Depsipeptide And Uses Thereofapplication
- Depsipeptides And Uses Thereofapplication
- Pharmaceutical Compositions Comprising Teixobactinapplication
- Pharmaceutical Compositions Comprising Teixobactingranted
- Novel Depsipeptides And Uses Thereofgranted
- Depsipeptide And Uses Thereofgranted
- Novel Depsipeptides And Uses Thereofgranted
- Depsipeptide And Uses Thereofgranted
- Methods For Producing A Depsipeptidegranted
- Novel Antibioticsapplication
- Depsipeptide And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.